Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: J Am Geriatr Soc. 2023 Sep 14;71(11):3367–3375. doi: 10.1111/jgs.18590

Table 1 –

Baseline study population characteristics stratified by malnutrition status

Characteristic, n (%) Overall, N = 231 Malnutrition Absent (MNA-SF Score > 11), N = 134 Malnutrition Present (MNA-SF Score ≤ 11), N = 97 P-value
Socio-demographics
Age in years, median (IQR) 73 (64, 81) 74 (68, 80) 72 (60, 82) 0.19
Women 152 (65.8%) 87 (64.9%) 65 (67.0%) 0.74
White Race 170 (73.6%) 92 (68.7%) 78 (80.4%) 0.045
Non-White Race 61 (26.4%) 42 (31.3%) 19 (19.6%)
Hispanic Ethnicity 19 (8.2%) 12 (9.0%) 7 (7.2%) 0.26
Comorbid conditions
Coronary Artery Disease 64 (27.7%) 37 (27.6%) 27 (27.8%) 0.97
Atrial Fibrillation 99 (42.9%) 62 (46.3%) 37 (38.1%) 0.22
Diabetes Mellitus 96 (41.6%) 52 (38.8%) 44 (45.4%) 0.32
Hypertension 186 (80.5%) 108 (80.6%) 78 (80.4%) 0.97
COPD 48 (20.8%) 26 (19.4%) 22 (22.7%) 0.54
Current Smoker 5 (2.2%) 2 (1.5%) 3 (3.1%) 0.65
Obesity 146 (63.2%) 86 (64.2%) 60 (61.9%) 0.72
BMI in kg/m2, median (IQR) 33 (27, 40) 32 (28, 38) 33 (27, 42) 0.62
Systolic BP in mmHg, median (IQR) 130 (117, 142) 134 (119, 148) 124 (115, 138) 0.004
eGFR, median (IQR) 62 (44, 80) 63 (45, 82) 59 (42, 79) 0.39
HF Characteristics
Heart failure diagnosed within previous 18 months 63 (27.3%) 27 (20.1%) 36 (37.1%) 0.004
NYHA Class 0.53
 1 7 (3.0%) 4 (3.0%) 3 (3.1%)
 2 77 (33.3%) 41 (30.6%) 36 (37.1%)
 3 138 (59.7%) 85 (63.4%) 53 (54.6%)
 4 9 (3.9%) 4 (3.0%) 5 (5.2%)
LVEF, median (IQR) 62 (60, 67) 62 (60, 67) 61 (60, 67) 0.87
MAGGIC Score, median (IQR) 22 (16, 26) 21 (17, 26) 22 (16, 27) 0.73
All-cause hospitalization within prior 6 months 113 (48.9%) 61 (45.5%) 52 (53.6%) 0.22
Baseline medication use
Beta Blocker 135 (58.4%) 74 (55.2%) 61 (62.9%) 0.24
ACE-I/ARB 86 (37.2%) 57 (42.5%) 29 (29.9%) 0.050
Diuretics 186 (80.5%) 104 (77.6%) 82 (84.5%) 0.19
Statins 157 (68.0%) 96 (71.6%) 61 (62.9%) 0.16

BP: Blood Pressure; BMI: Body Mass Index; NYHA: New York Heart Association; COPD: Chronic Obstructive Pulmonary Disease; ACE-I: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; MAGGIC: Meta-Analysis Global Group in Chronic (MAGGIC) heart failure; LVEF: Left Ventricle Ejection Fraction; CAD: Coronary Artery Disease; CKD: Chronic Kidney Disease; IQR: Interquartile Range; eGFR: estimated glomerular filtration rate